Glioblastoma survival: has it improved? Evidence from population-based studies.
about
Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice.Targeting immune checkpoints in malignant gliomaProspects of immune checkpoint modulators in the treatment of glioblastomaFatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and Review of the LiteratureA molecular hypothesis to explain direct and inverse co-morbidities between Alzheimer's Disease, Glioblastoma and Lung cancerDynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialSecond Generation Amphiphilic Poly-Lysine Dendrons Inhibit Glioblastoma Cell Proliferation without Toxicity for Neurons or AstrocytesCD44 promotes the migration of bone marrow-derived mesenchymal stem cells toward gliomaOverexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ.Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cellsChemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis toolDetermining priority signs and symptoms for use as clinical outcomes assessments in trials including patients with malignant gliomas: Panel 1 Report.Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells.Elucidating immunometabolic targets in glioblastoma.Subtotal Resection of a Thalamic Glioblastoma Multiforme through Transsylvian Approach.Extent of Resection in Newly Diagnosed Glioblastoma: Impact of a Specialized Neuro-Oncology Care Center.Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma.Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas.Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space
P2860
Q27313690-A7DF6228-CB0D-4EC5-898D-E06B6F9119E2Q28072012-6D71616D-8FE4-40B6-8B14-DD25D3D184D3Q28081371-F3AC22C9-ED41-475F-9597-EB9FD0666839Q33436238-183822CA-F91D-4A62-B69B-CD300A8A918EQ33860823-BEEBBF82-1E57-4543-9883-2556687390C1Q35815291-29A28474-4323-4A58-8002-64637647A1A2Q36188526-E81E84BC-4668-4B8C-93FB-BE6D1F9F5105Q36741362-E04602A7-B616-4ECA-A3CF-B1433668ECDDQ37699166-7F13E58A-DA88-4EC3-B49C-4B22942F3EB5Q37732931-068614B7-A0CE-43D1-A7F7-655D70723C41Q38611037-D87F3AF9-9662-451D-8FD7-4F38A8FBB903Q38779273-64E60880-8004-4687-8AE2-03D46F54E2D3Q39174318-8E28C4FA-6B5A-4F1A-A35C-D4C405FA2778Q41476692-04B394DD-2BE4-4072-9341-EFFF611889F2Q46664541-78F5D801-08AC-45AB-A7E6-2A368078B6D7Q47101328-5F31D1BF-AAD3-419E-89B8-D1042D8FB246Q47218511-D250DEA0-DA8F-4586-B252-BF0274973ADEQ47773621-EB28C7E1-3551-4020-8A1A-57E1E6C7779BQ55047554-D5245413-7F00-4C30-9484-F3BADFD25E27Q55411543-28391DB0-0500-40FA-9D2D-2E8BD92B2AF6Q55457206-7EED24D0-8291-46FE-8FC4-3FB344B88ADEQ56333957-D282F23E-F075-4B6D-BE16-EACFAC863B1B
P2860
Glioblastoma survival: has it improved? Evidence from population-based studies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Glioblastoma survival: has it improved? Evidence from population-based studies.
@en
type
label
Glioblastoma survival: has it improved? Evidence from population-based studies.
@en
prefLabel
Glioblastoma survival: has it improved? Evidence from population-based studies.
@en
P1476
Glioblastoma survival: has it improved? Evidence from population-based studies
@en
P2093
Luc Bauchet
P304
P356
10.1097/WCO.0000000000000144
P577
2014-12-01T00:00:00Z